{"id":295337,"date":"2025-02-07T00:00:00","date_gmt":"2025-02-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0031-2021-biopharma-prostate-cancer-unmet-need-unmet-need-metastatic-hormone-sensitive\/"},"modified":"2026-03-31T10:27:07","modified_gmt":"2026-03-31T10:27:07","slug":"unneon0031-2025-biopharma-prostate-cancer-unmet-need-unmet-need-metastatic-hormone-sensitive-prostate-cancer-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0031-2025-biopharma-prostate-cancer-unmet-need-unmet-need-metastatic-hormone-sensitive-prostate-cancer-us-eu\/","title":{"rendered":"Prostate Cancer &#8211; Unmet Need &#8211; Unmet Need &#8211; Metastatic Hormone-Sensitive Prostate Cancer (US\/EU)"},"content":{"rendered":"<p>Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer. Androgen receptor inhibitors such as abiraterone and Xtandi (Pfizer \/ Astellas) are common treatments for metastatic hormone-sensitive prostate cancer (<abbr title=\"metastatic hormone-sensitive prostate cancer\">mHSPC<\/abbr>). These drugs compete with next-generation hormonal therapies such as Erleada (Johnson &#038; Johnson) and Nubeqa (Bayer). Despite the availability of these androgens in combination with androgen deprivation therapy (<abbr title=\"androgen deprivation therapy\">ADT<\/abbr>), <abbr title=\"metastatic hormone-sensitive prostate cancer\">mHSPC<\/abbr> often progresses, highlighting the need for more-effective, safer therapies and underscoring the significant commercial opportunity in this space.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which attributes most influence prescribers\u2019 choice of therapy for <abbr title=\"metastatic hormone-sensitive prostate cancer\">mHSPC<\/abbr>?<\/li>\n<li>How do key current therapies, in combination with <abbr title=\"androgen deprivation therapy\">ADT<\/abbr>, perform on key treatment drivers and goals for this patient population?<\/li>\n<li>What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?<\/li>\n<li>How much are medical oncologists willing to compromise on the clinical benefits of a hypothetical new treatment for newly diagnosed <abbr title=\"metastatic hormone-sensitive prostate cancer\">mHSPC<\/abbr>, taking into consideration a better price, and vice versa?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 32 European medical oncologists fielded in December 2024<\/p>\n<p><strong>Key drugs:<\/strong> Abiraterone, Xtandi, Erleada, Nubeqa<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the TPP Simulator.<\/li>\n<\/ul>\n<p><strong>KEY FEATURE<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-295337","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295337\/revisions"}],"predecessor-version":[{"id":575827,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295337\/revisions\/575827"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}